Unity Biotechnology (9U9) Stock Overview
A biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
9U9 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Unity Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.085 |
| 52 Week High | US$2.62 |
| 52 Week Low | US$0.076 |
| Beta | 0.93 |
| 1 Month Change | -87.14% |
| 3 Month Change | -89.98% |
| 1 Year Change | -93.64% |
| 3 Year Change | -98.64% |
| 5 Year Change | n/a |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9U9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.0% | 2.1% | -0.5% |
| 1Y | -93.6% | -10.2% | 18.2% |
Return vs Industry: 9U9 underperformed the German Biotechs industry which returned -12.4% over the past year.
Return vs Market: 9U9 underperformed the German Market which returned 19.1% over the past year.
Price Volatility
| 9U9 volatility | |
|---|---|
| 9U9 Average Weekly Movement | 30.4% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 9U9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9U9's weekly volatility has increased from 21% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 16 | n/a | unitybiotechnology.com |
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an a-Klotho hormone drug candidate for multiple neurology indications.
Unity Biotechnology, Inc. Fundamentals Summary
| 9U9 fundamental statistics | |
|---|---|
| Market cap | €1.56m |
| Earnings (TTM) | -€23.73m |
| Revenue (TTM) | n/a |
Is 9U9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9U9 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$12.06m |
| Gross Profit | -US$12.06m |
| Other Expenses | US$15.45m |
| Earnings | -US$27.50m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 9U9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/28 13:21 |
| End of Day Share Price | 2025/07/28 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Unity Biotechnology, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Andrew Fein | H.C. Wainwright & Co. |
| Matthew Caufield | H.C. Wainwright & Co. |